Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties.

Øystein Kalsnes JørstadStian FossTorleif Tollefsrud GjølbergSimone MesterMari Nyquist-AndersenMagne Sand SivertsenDag FossumEspen GleditschMorten Carstens MoeJan Terje Andersen

Published in: International journal of retina and vitreous (2023)

Withdrawal and storage of faricimab in syringes for up to day 37 did not impair the structure and bi-specific binding properties of the therapeutic antibody.

Keyphrases

dna binding
vascular endothelial growth factor
binding protein
ultrasound guided